Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
NCT06083753 · View on ClinicalTrials.gov ↗
Study Summary
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PIPE-307 Dose A
- DRUG PIPE-307 Dose B
Study Locations (20)
Texas
- University of Texas Health Science Center at Houston — Houston
- Clinical Trial Network — Houston
- Bhupesh Dihenia, MD, PA — Lubbock
Arizona
- Xenosciences — Phoenix
- Arizona Neuroscience Research, LLC — Phoenix
Florida
- MS and Neuromuscular Center of Excellence — Clearwater
- Aqualane Clinical Research — Naples
New York
- Dent Neurologic Institute — Amherst
- Neurological Associates of Long Island, P.C. — Lake Success
Washington
- Virginia Mason Medical Center — Seattle
- UW Medicine MS Center — Seattle
California
- Alta Bates Summit Medical Center — Berkeley
Colorado
- Colorado Springs Neurological Associates — Colorado Springs
Georgia
- Shepherd Center — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2025-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06083753
The ClinicalTrials.gov registry entry for NCT06083753 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Contineum Therapeutics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06083753 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Texas, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06083753 about?
NCT06083753 is a clinical study titled "Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis". This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
What is the current status of trial NCT06083753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2023-11-06. Estimated completion is 2025-08-04.
What conditions does trial NCT06083753 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06083753?
The interventions under investigation include: Placebo (DRUG), PIPE-307 Dose A (DRUG), PIPE-307 Dose B (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06083753?
This trial is sponsored by Contineum Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06083753 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.